Literature DB >> 21788052

Utilization trends in prostate cancer therapy.

Deepak A Kapoor1, Shawn H Zimberg, Lisa M Ohrin, Willie Underwood, Carl A Olsson.   

Abstract

PURPOSE: We determined therapeutic trends in the management of adenocarcinoma of the prostate, and in the case of intensity modulated radiation therapy we investigated whether site of service influenced those trends.
MATERIALS AND METHODS: A variety of CPT codes to treat adenocarcinoma of the prostate were extracted from the Medicare Part B 5% sample for the years 2006 to 2008 inclusive. Data were stratified by year, type of service and, in the case of radiation therapy, site of service. Treatment trends were calculated by indexing the total number of Medicare beneficiaries receiving a service against needle biopsies of the prostate.
RESULTS: The percentage of Medicare beneficiaries receiving therapy indexed to needle biopsies of the prostate increased from 43.8% in 2006 to 49.0% in 2008. Trends in radiation and surgery were similar with 11.5% and 13% increases in each modality, respectively. Total Medicare beneficiaries receiving intensity modulated radiation therapy and laparoscopic radical prostatectomy increased by 25.4% and 22.1%, respectively, while Medicare beneficiaries treated with open radical prostatectomy and 3-dimensional conformal radiation therapy decreased by 27.9% and 37.6%, respectively. The pattern of use for intensity modulated radiation therapy was similar in physician office and hospital facility settings, increasing from 7.3% to 11.1% and 8.3% to 11.3% of Medicare beneficiaries indexed to needle biopsies of the prostate receiving intensity modulated radiation therapy at these sites in 2008, respectively.
CONCLUSIONS: Treatment trends in surgery and radiation strongly favor newer technologies, and in the case of intensity modulated radiation therapy, utilization trends for treatment of adenocarcinoma of the prostate are similar across all sites of service.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21788052     DOI: 10.1016/j.juro.2011.04.075

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Preserving Independent Urology: LUGPA's First Decade.

Authors:  Neal D Shore; Deepak A Kapoor; Evan R Goldfischer; David C Chaikin; Earl L Walz; R Jonathan Henderson; Richard G Harris; Robert D Asinof; Gary M Kirsh
Journal:  Rev Urol       Date:  2019

2.  Effect of practice integration between urologists and radiation oncologists on prostate cancer treatment patterns.

Authors:  Justin E Bekelman; Gita Suneja; Thomas Guzzo; Craig Evan Pollack; Katrina Armstrong; Andrew J Epstein
Journal:  J Urol       Date:  2013-02-08       Impact factor: 7.450

3.  Influence of Geography on Prostate Cancer Treatment.

Authors:  Chad Tang; Xiudong Lei; Grace L Smith; Hubert Y Pan; Karen E Hoffman; Rachit Kumar; Brian F Chapin; Ya-Chen Tina Shih; Steven J Frank; Benjamin D Smith
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-12-13       Impact factor: 7.038

4.  Locoregional prostate cancer treatment pattern variation in independent cancer centers: policy effect, patient preference, or physician incentive?

Authors:  Andrew S Camarata; Dana C Nickleach; Ashesh B Jani; Peter J Rossi
Journal:  Health Serv Insights       Date:  2015-04-15

5.  Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project.

Authors:  K C Cary; S Punnen; A Y Odisho; M S Litwin; C S Saigal; M R Cooperberg
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-02-10       Impact factor: 5.554

6.  Consulting "Dr. Google" for Prostate Cancer Treatment Options: A Contemporary Worldwide Trend Analysis.

Authors:  Giovanni E Cacciamani; Silvia Bassi; Marco Sebben; Anna Marcer; Giorgio I Russo; Andrea Cocci; Paolo Dell'Oglio; Luis G Medina; Nima Nassiri; Alessandro Tafuri; Andre Abreu; Antonio B Porcaro; Alberto Briganti; Francesco Montorsi; Inderbir S Gill; Walter Artibani
Journal:  Eur Urol Oncol       Date:  2019-07-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.